Sellas Life Sciences Group Inc
Change company Symbol lookup
Select an option...
SLS Sellas Life Sciences Group Inc
TSLA Tesla Inc
ISNPY Intesa Sanpaolo SpA
BAC Bank of America Corp
XAN-C Exantas Capital Corp
FRAN Francesca's Holdings Corp
SPA Sparton Corp
MPLX MPLX LP
CACI CACI International Inc
ABEV Ambev SA
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.

Closing Price
$1.65
Day's Change
-0.03 (-1.79%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.71
Day's Low
1.62
Volume
(Light)
Volume:
756,199

10-day average volume:
2,550,616
756,199
  • Prev Close
    1.68
  • Today's Open
    1.66
  • Day's Range
    1.62-1.71
  • Avg Vol (10-day)
    2.6M
  • Last (time)
    4:00p ET 11/16/18
  • Last (size)
    100
  • 52-Wk Range
    0.8001 - 11.09
    LowHigh
  • (04/03/18 - 08/20/18)
    106.22%
  • 146.3%
  • Market Cap
    36.3M
  • Shares Outstanding
    22.0M
  • -9.16
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 1.0
  • 28.20
  • (% of float 10/31/18)
    10.94

Latest News

November 15, 2018
7:45 am ET
Globe Newswire
November 09, 2018
8:55 am ET
Globe Newswire
8:30 am ET
Globe Newswire
November 08, 2018
8:45 am ET
Globe Newswire
November 02, 2018
9:31 am ET
PR Newswire
October 22, 2018
7:00 am ET
Globe Newswire
October 19, 2018
8:05 am ET
Globe Newswire
October 15, 2018
8:30 am ET
Globe Newswire
October 02, 2018
4:01 pm ET
Globe Newswire
September 24, 2018
4:30 pm ET
Globe Newswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2018 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2018. All rights reserved.